Castle Creek Biosciences

About Castle Creek Biosciences

Castle Creek Biosciences, Inc. is a leading cell and gene therapy company focused on creating optimal treatments for genetic diseases. Their mission is to develop novel gene therapies to improve the lives of patients and families affected by devastating genetic conditions.

Products & Services

D-Fi Gene Therapy:A gene therapy treatment for Dystrophic Epidermolysis Bullosa (DEB), currently in a registrational Phase 3 trial.

Autologous Fibroblast Technology:A technology platform used in the development of therapies for genetic diseases.

Specialties

Cell Therapy Gene Therapy Treatment of Genetic Diseases Dystrophic Epidermolysis Bullosa (DEB)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Royalty Financing T: - FT: Royalty Financing	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2025-02-25 FD: 2025-02-25	4 investors

Royalty Financing Latest

2025-02-25

$75.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Matthew Gantz

Chairman and Chief Executive Officer

M

Mayo Pujols

Chief Operating Officer

D

David Chu

Chief Medical Officer

D

David Chu, M.D., Ph.D., F.A.A.D.

Chief Medical Officer

M

Michael Townsley

Head of Quality Assurance

C

Christopher J. Larson

Vice President, Quality Control

View 7 more team members with Pro

Unlock Full Team Directory

Recent News